GlassScriptPhysician profile
Mi Soo Woo
NPI 1245806389
$3,034.50
in general payments reported to CMS, 2019-2025
30 companies · $16.27 in 2025
The $16.27 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $829 · 2022: $628 · 2023: $1,297 · 2024: $264 · 2025: $16.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.98 | 2021-2022 | |
| Abbvie INC. | $288.25 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $260.31 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $211.26 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $186.07 | 2021-2023 | Camzyos |
| Abbott Laboratories | $158.67 | 2024 | Xience Skypoint |
| Janssen Pharmaceuticals, INC | $137.82 | 2022-2024 | Xarelto |
| Pfizer INC. | $131.60 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $120.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $120.46 | 2022-2023 | Brilinta, Farxiga |
| Cardiovascular Systems INC. | $118.63 | 2023 | Diamondback Coronary |
| Janssen Biotech, INC. | $115.18 | 2021 | |
| Amgen INC. | $88.90 | 2022-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.95 | 2023-2024 | Jardiance |
| Scpharmaceuticals INC. | $85.42 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $85.36 | 2021-2022 | |
| Novo Nordisk INC | $55.42 | 2023 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $55.41 | 2023 | Injectafer |
| Itamar Medical INC | $52.72 | 2023-2025 | Watchpatone |
| Redhill Biopharma INC. | $51.98 | 2022 | |
| Qol Medical, LLC | $51.44 | 2021 | |
| Intercept Pharmaceuticals, INC. | $39.12 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.15 | 2021 | |
| Philips North America LLC | $31.96 | 2023 | |
| Ironwood Pharmaceuticals, INC | $24.66 | 2022 | |
| Ardelyx, INC. | $23.53 | 2022 | |
| Tersera Therapeutics LLC | $21.01 | 2021 | |
| Medicomp INC | $20.34 | 2023 | Telepatch Cardiac Monitor |
| Teleflex LLC | $15.77 | 2023 | Manta |
| Vivus LLC | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mi Soo Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.